Cargando…

Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

INTRODUCTION: Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying anti-rheuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joven, Beatriz, Hernández Sánchez, Raquel, Pérez-Pampín, Eva, Aragón Díez, Ángel, Almodóvar, Raquel, Martínez-Ferrer, Ángels, Belzunegui, Joaquín, Rubio, Esteban, Díaz-Cerezo, Silvia, Moyano, Sebastián, Gómez-Barrera, Manuel, Yébenes, María, Núñez, Mercedes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468471/ https://www.ncbi.nlm.nih.gov/pubmed/37481752 http://dx.doi.org/10.1007/s40744-023-00584-8

Ejemplares similares

Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
por: Joven, Beatriz, et al.
Publicado: (2023)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
por: Miller, John, et al.
Publicado: (2021)

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience
por: Braña, Ignacio, et al.
Publicado: (2023)

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
por: Valero-Martínez, Cristina, et al.
Publicado: (2023)

Results of Mentoring in the Psychosocial Well-Being of Young Immigrants and Refugees in Spain
por: Sánchez-Aragón, Anna, et al.
Publicado: (2020)

A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
por: Mease, Philip, et al.
Publicado: (2019)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
por: Gladman, Dafna D., et al.
Publicado: (2019)

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study
por: Murage, Mwangi J., et al.
Publicado: (2021)

Intracellular targeting of STIP1 inhibits human cancer cell line growth
por: Lin, Chiao-Yun, et al.
Publicado: (2021)

Parkinson’s Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1
por: Tan, Jolene Su Yi, et al.
Publicado: (2022)

Beyond COVID: Reframing the Global Problematique with STiP (Systems Thinking in Practice)
por: Ison, Raymond L.
Publicado: (2023)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
por: Berman, Julia, et al.
Publicado: (2021)

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2022)

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
por: Eder, Lihi, et al.
Publicado: (2022)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

The Expression of FOXE-1 and STIP-1 in Papillary Thyroid Carcinoma and Their Relationship with Patient Prognosis
por: M Fouad, Enas, et al.
Publicado: (2018)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
por: Kirkham, Bruce, et al.
Publicado: (2021)

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center
por: Chiu, I-Heng, et al.
Publicado: (2023)

Ixekizumab-induced alopecia areata
por: Eldirany, Sherif A., et al.
Publicado: (2019)

Tumor Stress-Induced Phosphoprotein1 (STIP1) as a Prognostic Biomarker in Ovarian Cancer
por: Chao, Angel, et al.
Publicado: (2013)

Hyperactivity and attention deficits in mice with decreased levels of stress-inducible phosphoprotein 1 (STIP1)
por: Beraldo, Flavio H., et al.
Publicado: (2015)

Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma
por: Wang, Jiang, et al.
Publicado: (2017)

JAK2-Mediated Phosphorylation of Stress-Induced Phosphoprotein-1 (STIP1) in Human Cells
por: Chao, Angel, et al.
Publicado: (2022)

Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study
por: Pascual, Julio, et al.
Publicado: (2023)

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
por: Combe, Bernard, et al.
Publicado: (2020)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Psoriatic arthritis screening: A systematic literature review and experts’ recommendations
por: Urruticoechea-Arana, Ana, et al.
Publicado: (2021)

Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma
por: Xu, Yi-Wei, et al.
Publicado: (2017)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Pyoderma gangrenosum in a patient on ixekizumab
por: Pollack, Ilana R., et al.
Publicado: (2021)

Ixekizumab‐induced urticarial drug eruption
por: Kaneoka, Ayaka, et al.
Publicado: (2023)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mujgc8jvbob150750gm5o2s0vg